Winners of Emerging Biotech Grant Program Announced
Issue: February 17, 2017
| Categories: Merck Topics
We are excited to announce the winners of our 2016 Emerging Biotech Grant Program in Europe. The winning submissions were selected based on the scientific and societal merit of the therapy in development as well as process challenges and expertise gaps that may impact ongoing development.
The four grant recipients are:
- GeneQuine Biotherapeutics (first prize), for developing novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need.
- TILT Biotherapeutics (second prize), for enabling tumor T-cell therapy with oncolytic viruses.
- Reneuron (third prize), for developing novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
- Magnus Life Science (fourth prize), for funding, building and managing companies to translate innovative, curiosity-driven science into therapeutics and devices that bring significant benefits to patients.
Each grant recipient will receive between €25,000 and €100,000 in products and services to accelerate their therapeutics to market.
To learn more click here
In This Same Issue